Texas Oncology and Aetna partnered to provide a practice-based program that reduced costs while maintaining adherence to treatment pathways and patient satisfaction in Medicare patients.
Bobby Daly, MD, MBA, and Ray D Page, DO, PhD, discuss the ramifications of clinical pathway vendor conflicts of interest and the potential issues of full transparency on the part of committee members.
Experts at the ACCC 44th Annual Meeting & Cancer Center Business Summit identified some of the largest drivers of change and rapidly evolving initiatives in oncology care, including costs of care and precision medicine initiatives.
Where the Pathways Conversation Turns to Action
Clinical pathways may require a deeper consideration of the patient experience in order to achieve the goals of the Triple Aim, according to Winston Wong, PharmD.
The simulation provided an opportunity for meeting attendees to observe the process by which oncologists determine initial diagnostic tests critical to treatment selection, the most appropriate treatment for each line of therapy, and criteria for subsequent treatment selection.
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting
Clinical pathways can act as a tool to assist oncology practices to promote testing of key biomarkers and subsequent selection of appropriate therapy.
The ASCO Task Force assessed six national pathway vendors to compare their products against the ASCO criteria for high-quality clinical pathways.
Shape Change at Every Step
Brian Bastean, PharmD, MBA, has identified some of the most important and influential research in recent months contributing to value-based care, health economics and outcomes research, and clinical pathways.